Evidence map›Paper›PMID 41134679›Full record

ArticleCancer research communications2025

Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal Cancer.

Ning Jin, Rebecca Hoyd, Ayse S Yilmaz, Jiangjiang Zhu, Yunzhou Liu, Malvenderjit S Jagjit Singh, Dennis J Grencewicz, Xiaokui Mo, Matthew F Kalady, Daniel W Rosenberg and 26 more

Abstract read
In one paragraph

Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors.

Ning JinDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-6689-4671
Rebecca HoydDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0003-1210-4491
Ayse S YilmazDepartment of Biomedical Informatics, The Ohio State University, Columbus, Ohio.ORCID 0000-0002-2954-0305
Jiangjiang ZhuHuman Nutrition Program, Department of Human Sciences, The Ohio State University, Columbus, Ohio.ORCID 0000-0002-4548-8949
Yunzhou LiuDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-9892-2438
Malvenderjit S Jagjit SinghDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0001-8198-9153
Dennis J GrencewiczDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-6322-2853
Xiaokui MoDepartment of Biomedical Informatics, The Ohio State University, Columbus, Ohio.ORCID 0000-0002-9797-2687
Matthew F KaladyDivision of Colon and Rectal Surgery, The Ohio State University, Columbus, Ohio.ORCID 0000-0003-1265-7483
Daniel W RosenbergDepartment of Medicine, UConn Health, Farmington, Connecticut.ORCID 0000-0003-2897-2613
Caroline E DravillasDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-3374-4909
Eric A SingerDivision of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0003-3991-0696
John D CarptenDepartment of Translational Genomics, University of Southern California, Los Angeles, California.ORCID 0000-0002-6862-2821
Carlos H F ChanDepartment of Surgery, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa.ORCID 0000-0003-3656-2470
Michelle L ChurchmanAster Insights, Hudson, Florida.ORCID 0000-0002-6560-1056
Nicholas DenkoDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0001-6875-734X
Frances Di ClementeDepartment of Precision Medicine Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.ORCID 0009-0009-2019-1274
Rebecca D DoddDepartment of Internal Medicine, The University of Iowa, Iowa City, Iowa.ORCID 0000-0001-7295-1882
Islam EljilanyClinical Science Lab - Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0001-6387-5419
Naomi FeiDepartment of Internal Medicine, The University of Iowa, Iowa City, Iowa.ORCID 0000-0001-9278-3521
Sheetal HardikarDepartment of Population Health Sciences, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah.ORCID 0000-0003-0292-6168
Alexandra P IkeguchiDepartment of Hematology/Oncology, Stephenson Cancer Center - The University of Oklahoma, Oklahoma City, Oklahoma.ORCID 0000-0002-4448-9755
Anjun MaDepartment of Biomedical Informatics, The Ohio State University, Columbus, Ohio.ORCID 0000-0001-6269-398X
Qin MaDepartment of Biomedical Informatics, The Ohio State University, Columbus, Ohio.ORCID 0000-0002-3264-8392
Martin D McCarterDepartment of Surgery, University of Colorado School of Medicine, Aurora, Colorado.ORCID 0000-0001-8174-1713
Afaf E G OsmanDivision of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-3688-4683
Gregory RiedlingerDepartment of Precision Medicine Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.ORCID 0000-0001-5690-7777
Lary A RobinsonThoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0003-4579-0141
Bryan P SchneiderDivision of Hematology/Oncology, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana.ORCID 0000-0003-1868-7739
Ahmad A TarhiniDepartment of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-3193-9702
Gabriel TinocoDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0002-2565-6124
Jane C FigueiredoSamuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, West Hollywood, California.ORCID 0000-0001-8040-3341
Yousef ZakhariaDepartment of Surgery, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa.ORCID 0000-0001-9480-2626
Cornelia M UlrichDepartment of Population Health Sciences, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah.ORCID 0000-0001-7641-059X
Aik Choon TanDepartment of Oncological Sciences, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah.ORCID 0000-0003-2955-8369
Daniel SpakowiczDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0003-2314-6435

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Translational Training Grant in Experimental TherapeuticsK12CA133250 · NCI · OHIO STATE UNIVERSITY · PI WILLIAM E. CARSON, Rosa Lapalombella · 2008 to 2026
$15.0M
The Ohio State University Center for Clinical and Translational Science (UL1)UL1TR000090 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2012 to 2013
$7.9M
Project 3: GLP1R and GIPR Agonists in GEP NETs ProjectP50CA302572 · NCI · UNIVERSITY OF IOWA · PI DAWN E QUELLE · 2025 to 2026
$6.5M
Geriatric assessment domains in relation to treatment outcomes among older adults with colorectal cancerR01AG083580 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sheetal Hardikar · 2024 to 2026
$2.3M
The microbiome in older adults with lung cancer: association of treatment regimens and diet with protective microbial profilesK01AG070310 · NIA · OHIO STATE UNIVERSITY · PI SPAKOWICZ, DANIEL J. · 2021 to 2025
$583k
Alpha Omega Alpha Honor Medical Society (AOA)American Cancer Society (ACS)Autism Speaks AS1695National Cancer Institute (NCI) K12CA133250National Cancer Institute (NCI) P30CA016058National Center for Advancing Translational Sciences (NCATS) 8UL1TR000090-05National Institute on Aging (NIA) K01AG070310National Institutes of Health (NIH) P30CA042014NCATS NIH HHS UL1 TR000090NCI NIH HHS K12 CA133250NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA042014NCI NIH HHS P50 CA302572NCI NIH HHS U01 CA206110NIA NIH HHS K01 AG070310NIA NIH HHS R01 AG083580Ohio State University (OSU)
6 · The paper itself

Abstract

The incidence of colorectal cancer in young adults (age of diagnosis <50 years) has been rapidly increasing. Although ∼20% of early-onset colorectal cancer (EOCRC) cases are due to germline mutations, the etiology of the majority of EOCRC cases remains poorly understood. Nongenetic factors such as environmental exposure and lifestyle changes are likely to have a direct link to the increased incidence of sporadic EOCRC. We hypothesize that such factors may be observable as alterations in the epigenome, microbiome, and immunome. We characterized the DNA methylation (DNAm) signature and measured DNAm age in EOCRC by using The Cancer Genome Atlas (TCGA). Furthermore, we carefully identified intratumoral microbes from TCGA and the Oncology Research Information Exchange Network datasets and then related the microbes to deconvolved immune cell abundances in EOCRC. We observed that the DNAm age in the EOCRC cohort was 12 years older when compared with the average-onset colorectal cancer (AOCRC) cohort, using three different epigenetic clocks. Differentially methylated sites associated with gene expression include cAMP-responsive element binding protein signaling in neurons, G protein-coupled receptor signaling, phagosome formation, and S100 family signaling. These differences were validated in the gene expression data from TCGA and the Oncology Research Information Exchange Network. When comparing the intratumoral microbes between EOCRC and AOCRC, no consistent differences were observed. Interestingly, the most abundant microbes interacted with the immune systems differently between the EOCRC and AOCRC tumors, characterized by more and larger positive correlations in EOCRC. These data suggest that epigenetic modulation and accelerated aging may play a key role in the development of EOCRC. SIGNIFICANCE: We investigated whether environmentally driven factors contribute to EOCRC. We observed accelerated epigenetic aging in EOCRC and epigenetic changes associated with chronic inflammation. Tumor immune cell abundances correlated more strongly with microbes in EOCRC than in AOCRC. These data suggest a dysregulation of the immune response in EOCRC, driving chronic inflammation and tissue aging.

Indexed as

Colorectal NeoplasmsEpigenesis, GeneticGastrointestinal MicrobiomeAdultAge of OnsetDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedYoung Adult

Identifiers

PMID41134679
PMCPMC12606411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.